Low-Dose Naltrexone ALS Trial

Overview

Low-dose naltrexone (LDN) has been investigated as a potential treatment for amyotrophic lateral sclerosis (ALS). Naltrexone is an opioid receptor antagonist typically used at high doses (50-100mg) to treat opioid and alcohol addiction. However, at low doses (3-4.5mg), it is believed to have distinct immunomodulatory and neuroprotective properties that may be beneficial in neurodegenerative diseases[@lowdose2014].

ALS is a progressive neurodegenerative disorder affecting motor neurons in the brain and spinal cord. The disease leads to muscle weakness, paralysis, and typically fatal respiratory failure within 2-5 years of onset. Despite extensive research, only two disease-modifying therapies (riluzole and edaravone) have received regulatory approval, highlighting the urgent need for novel therapeutic approaches. The neuroinflammation that accompanies ALS has emerged as a promising therapeutic target, and LDN's immunomodulatory properties prompted clinical investigation in this patient population[@gill2019].

Background on Low-Dose Naltrexone

Historical Context

Naltrexone was originally developed in the 1960s as an oral opioid antagonist. At standard doses (50-100mg daily), it blocks opioid receptors completely, preventing the effects of exogenous opioids and reducing drug craving in addiction treatment. The observation that much lower doses (1/10th to 1/50th of standard) could produce opposite effects led to the development of the LDN phenomenon in the 1980s[@opioidreview2012].

Pharmacological Properties

Overview

Low-dose naltrexone (LDN) has been investigated as a potential treatment for amyotrophic lateral sclerosis (ALS). Naltrexone is an opioid receptor antagonist typically used at high doses (50-100mg) to treat opioid and alcohol addiction. However, at low doses (3-4.5mg), it is believed to have distinct immunomodulatory and neuroprotective properties that may be beneficial in neurodegenerative diseases[@lowdose2014].

ALS is a progressive neurodegenerative disorder affecting motor neurons in the brain and spinal cord. The disease leads to muscle weakness, paralysis, and typically fatal respiratory failure within 2-5 years of onset. Despite extensive research, only two disease-modifying therapies (riluzole and edaravone) have received regulatory approval, highlighting the urgent need for novel therapeutic approaches. The neuroinflammation that accompanies ALS has emerged as a promising therapeutic target, and LDN's immunomodulatory properties prompted clinical investigation in this patient population[@gill2019].

Background on Low-Dose Naltrexone

Historical Context

Naltrexone was originally developed in the 1960s as an oral opioid antagonist. At standard doses (50-100mg daily), it blocks opioid receptors completely, preventing the effects of exogenous opioids and reducing drug craving in addiction treatment. The observation that much lower doses (1/10th to 1/50th of standard) could produce opposite effects led to the development of the LDN phenomenon in the 1980s[@opioidreview2012].

Pharmacological Properties

LDN operates through a unique mechanism distinct from high-dose naltrexone:

Trial Details

| Parameter | Value |
|-----------|-------|
| Phase | Phase 2 |
| Status | Completed |
| Drug | Naltrexone hydrochloride (low-dose) |
| Dosage | 3-4.5 mg daily |
| Patient Population | Adults with definite or probable ALS (El Escorial criteria) |
| Duration | 6-12 months |
| Design | Randomized, double-blind, placebo-controlled |
| Primary Endpoint | Safety and tolerability |
| Secondary Endpoints | ALSFRS-R decline rate, pulmonary function, survival |

Patient Selection Criteria

Inclusion Criteria:

• Age 18-80 years
• Definite or probable ALS per El Escorial criteria
• Disease duration less than 36 months
• FVC greater than 50% predicted
• Stable on riluzole (if using) for at least 30 days
• Able to swallow tablets

• Active opioid use or dependence
• History of opioid antagonism therapy
• Significant renal or hepatic impairment
• Active malignancy
• Pregnancy or nursing

Mechanism of Action

Low-dose naltrexone operates through several proposed mechanisms relevant to ALS pathology:

Opioid Receptor Modulation

The initial blockade of opioid receptors triggers a compensatory upregulation of endogenous opioid production[@opioidreview2012]:

• Temporary Antagonism: Brief blockade of opioid receptors triggers upregulation
• Endorphin Enhancement: Increased endogenous opioid peptide production
• Met-enkephalin Increase: Elevated met-enkephalin levels have immunomodulatory effects

Anti-inflammatory Effects

Neuroinflammation is a hallmark of ALS, with activated microglia and astrocytes contributing to motor neuron damage. LDN modulates this response:

• Microglial Suppression: Reduces pro-inflammatory microglial activation through TLR4 antagonism
• TNF-α Reduction: Decreases tumor necrosis factor-alpha signaling, a key mediator of neuroinflammation
• Cytokine Modulation: Alters balance between pro-inflammatory (IL-1β, IL-6) and anti-inflammatory (IL-10) cytokines[@gill2019]

Neuroprotection

Additional neuroprotective mechanisms include:

• Reduced Glial Activation: Dampens astrocyte and microglial reactivity
• Anti-excitotoxic Effects: May modulate glutamate signaling, as excessive glutamate excitotoxicity contributes to motor neuron death in ALS
• Neuronal Survival: Promotes survival pathways in motor neurons through increased neurotrophic factor production

Trial Design

The clinical trial employed:

• ALSFRS-R decline rate
• Slow vital capacity (SVC) as measure of respiratory function
• Survival time
• Quality of life measures (ALSAQ-40)

Outcome Measures

Primary Outcome:

• Number and severity of adverse events
• Discontinuation rate due to adverse effects
• Laboratory abnormalities

• ALSFRS-R: Revised ALS Functional Rating Scale, a validated measure of physical function in ALS
• SVC: Slow vital capacity, measuring respiratory function
• Survival: Time to death or tracheostomy
• Biomarkers: Inflammatory markers (TNF-α, IL-6) in blood and CSF

Results

Key findings from the trial:

Safety Profile

• Tolerability: Low-dose naltrexone was well-tolerated with minimal side effects
• Common Adverse Events: Generally mild and transient (headache, nausea, sleep disturbance)
• No Serious Drug-Related Events: No significant safety signals observed

Efficacy Outcomes

• Primary Endpoint: Met — LDN demonstrated acceptable safety and tolerability
• ALSFRS-R Decline: No significant difference in decline rate between LDN and placebo groups
• Survival: No significant difference in survival between groups
• Respiratory Function: No significant difference in SVC decline

Exploratory Analyses

• Subgroup Finding: Suggested potential benefit in subset of patients with higher inflammatory markers at baseline
• Biomarker Changes: Some reduction in inflammatory markers observed, though not correlated with clinical outcomes

Conclusions

The trial demonstrated that LDN is safe in ALS patients but did not show disease-modifying effects in the overall population. The safety profile supports continued investigation in specific subpopulations or in combination with other therapies.

Clinical Significance

The LDN trials in ALS contribute to understanding of:

Immunomodulatory Approaches

Targeting neuroinflammation remains a promising strategy in ALS. While LDN did not show efficacy, the trial established that modulation of the immune system is feasible in ALS patients. Future studies may explore:

• Higher doses of naltrexone
• Combination with other immunomodulatory agents
• Biomarker-selected patient populations

Drug Repurposing

Evaluating existing drugs for new indications offers advantages:

• Established safety profiles
• Known pharmacokinetics
• Lower development costs
• Rapid clinical translation

Patient Selection

The exploratory finding suggesting benefit in patients with elevated inflammatory markers raises the possibility of biomarker-guided patient selection in future trials. This aligns with the broader movement toward precision medicine in neurology.

Combination Therapy

LDN may have potential as adjunct to other treatments:

• Synergistic immunomodulation with other agents
• Complementary mechanisms to riluzole or edaravone
• Low-risk addition to existing regimens

Comparison to Other Immunomodulatory Approaches in ALS

| Agent | Target | Status | Outcome |
|-------|--------|--------|---------|
| Minocycline | Microglia | Phase 3 | Failed[@meador2014] |
| Lithium | GSK-3β | Phase 2/3 | Mixed results |
| Ceftriaxone | Glutamate transport | Phase 3 | Failed |
| LDN | TLR4/opioid | Phase 2 | Failed (safety positive) |
| Edaravone | Oxidative stress | Approved | Modest benefit |

Ongoing Research

While the ALS trial was negative, LDN continues to be investigated in other neurological conditions:

• Fibromyalgia: Positive results in randomized trials[@younger2014]
• Multiple Sclerosis: Ongoing investigation
• Crohn's Disease: FDA approved for a related condition
• Parkinson's Disease: Preclinical and early clinical work

Related ALS Clinical Trials

• [Minocycline ALS Trial](/clinical-trials/minocycline-als) — Similar immunomodulatory approach, also failed
• [Lithium Carbonate ALS Trial](/clinical-trials/lithium-carbonate-als) — Different mechanism, mixed results
• [Ceftriaxone ALS Trial](/clinical-trials/ceftriaxone-als) — Glutamate modulation, failed
• [Edaravone Trial](/therapeutics/edaravone) — Approved disease-modifying therapy
• [Riluzole](/therapeutics/riluzole) — Original disease-modifying therapy

External Links

• [ClinicalTrials.gov](https://clinicaltrials.gov)
• [PubMed: Low-Dose Naltrexone in ALS](https://pubmed.ncbi.nlm.nih.gov/25425134/)
• [LDN Research Trust](https://www.lowdosenaltrexone.org)
• [ALS Association](https://www.als.org)

References

See Also

• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Microglia in Neurodegeneration](/diseases/neurodegeneration)
• [ALS Clinical Trials](/diseases/amyotrophic-lateral-sclerosis)
• [Immunomodulatory Therapies in ALS](/diseases/amyotrophic-lateral-sclerosis)

Pathway Diagram

The following diagram shows key molecular relationships for Low-Dose Naltrexone ALS Trial based on knowledge graph edges:

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Stress Granule Phase Separation Modulators](/hypothesis/h-97aa8486) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: G3BP1
• [Heat Shock Protein 70 Disaggregase Amplification](/hypothesis/h-5dbfd3aa) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: HSPA1A
• [PARP1 Inhibition Therapy](/hypothesis/h-69919c49) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: PARP1
• [Cryptic Exon Silencing Restoration](/hypothesis/h-4fabd9ce) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: TARDBP
• [Arginine Methylation Enhancement Therapy](/hypothesis/h-19003961) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: PRMT1
• [Cross-Seeding Prevention Strategy](/hypothesis/h-eea667a9) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: TARDBP
• [RNA Granule Nucleation Site Modulation](/hypothesis/h-fffd1a74) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: G3BP1
• [Axonal RNA Transport Reconstitution](/hypothesis/h-8196b893) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: HNRNPA2B1

Related Analyses:

• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving Low-Dose Naltrexone ALS Trial discovered through SciDEX knowledge graph analysis: